English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Diabetes mellitus (simply known as diabetes) is a long-lasting disorder of food metabolism characterized by hyperglycemia, originating due to defect in insulin secretion, insulin function or both leading to tissue and vascular damage and resulting in a variety of complications including retinopathy, cataract, neuropathy, nephropathy, ketoacidosis, disorders of cardiovascular system and foot ulcers (Bastaki, 2005; Cade, 2008; Grewal et al., 2016). Type 2 diabetes (T2D) affecting more than 90% of all the diabetic patients, is a long-term disordered food metabolism caused by declined insulin action (Kohei, 2010; Olokaba et al., 2012). Despite the fact that various types of oral antidiabetic drugs are available for the treatment of T2D, no single drug is useful for achieving longterm control of normal blood glucose levels in majority of patients. Due to this reason, general practitioners prescribe combination of antidiabetic agents for T2D therapy and overdose of antidiabetic medicines could lead to severe hypoglycemia resulting in brutal toxic and side effects (Olokaba et al., 2012). The medicinal chemists are currently focusing on development of novel safe antidiabetic medicines with biologically new mechanism of action which can be used as single drug with improved efficacy. Results from several recent reports, including emerging clinical reports, have demonstrated that small-molecule allosteric glucokinase (GK) activators may be able to achieve these objectives (Pal, 2009).

Molecular docking assessment of N-heteroaryl substituted benzamide derivatives as glucokinase activators